Chase Contino, MD
Clinical Cardiac Electrophysiology · Philadelphia, PANPI 1538429048
Payments from drug & device makers
Across 260 payments — averaging $128.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$15K
- Boston Scientific$10K
- Abbott$4K
- Philips North America LLC$2K
- Medical Device Business Services, Inc.$1K
- Novartis$482
- plus $2K from 24 others
What the payments were for
- Grants$21,40064%
- Travel & lodging$5,07115%
- Food & beverage$6,71720%
- Education$2471%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 25 | $14,876 |
| Boston Scientific | 31 | $9,772 |
| Abbott | 56 | $3,566 |
| Philips North America LLC | 8 | $1,537 |
| Medical Device Business Services, Inc. | 4 | $1,110 |
| Novartis | 35 | $482 |
| Biosense Webster, Inc. | 7 | $246 |
| Cvrx, Inc. | 6 | $242 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $186 |
| Amgen | 10 | $163 |
| Johnson & Johnson | 9 | $156 |
| E.r. Squibb & Sons, L.L.C. | 9 | $128 |
| Boehringer Ingelheim | 8 | $121 |
| Merck | 7 | $115 |
| Biotronik Inc. | 2 | $102 |
| Abiomed | 2 | $81 |
| AstraZeneca | 6 | $78 |
| Scpharmaceuticals Inc. | 4 | $70 |
| Pfizer | 4 | $63 |
| Sanofi-aventis U.S. LLC | 4 | $62 |
| Novo Nordisk | 4 | $61 |
| Amarin Pharma, Inc. | 4 | $58 |
| Cardiva Medical, Inc. | 2 | $32 |
| Chiesi USA, Inc. | 1 | $25 |
| Kestra Medical Technology Services, Inc. | 1 | $24 |
| Atricure, Inc. | 1 | $19 |
| United Therapeutics Corporation | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Angiodynamics, Inc. | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL BRADY$8,900
- AVEIR$1,771
- (9520) IGT Devices Undivided$1,343
- Carto 3 System$1,110
- EVERA MRI XT DR SURESCAN$773
- Micra$579
- QUADRA ASSURA$174
- Barostim Neo System$145
- COBALT DR MRI SURESCAN$130
- CardioMEMS HF System$129
- AURORA EV-ICD MRI SURESCAN$129
- GENERAL - THERAPIES$124
- Ensite Cardiac Mapping System$109
- General - CRM_CRM$103
- WATCHMAN FLX$103
- OCTARAY MAPPING CATHETER$102
How this compares
$33,435 in reported general payments places this provider in the 55th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.
See all clinical cardiac electrophysiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 218 | $293,434 |
| EntrestoSacubitril/Valsartan | 87 | $131,969 |
| JardianceEmpagliflozin | 50 | $69,776 |
| XareltoRivaroxaban | 59 | $60,626 |
| MultaqDronedarone Hcl | 13 | $19,627 |
| BrilintaTicagrelor | 13 | $16,241 |
| Metoprolol Succinate | 425 | $7,196 |
| Flecainide Acetate | 100 | $4,376 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 13 | $3,153 |
| Amiodarone Hcl | 88 | $3,085 |
| Bumetanide | 15 | $1,732 |
| Atorvastatin Calcium | 143 | $1,713 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 31 | $1,512 |
| Losartan Potassium | 100 | $1,062 |
| Amlodipine Besylate | 92 | $1,054 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $63 | $293,434218 claims |
| NovartisEntresto | $482 | $131,96987 claims |
| Boehringer IngelheimJardiance | $121 | $69,77650 claims |
| Johnson & JohnsonXarelto | $156 | $60,62659 claims |
| Sanofi-aventis U.S. LLCMultaq | $62 | $19,62713 claims |
| AstraZenecaBrilinta | $78 | $16,24113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.
Other clinical cardiac electrophysiology in Philadelphia
- Pasquale SantangeliPhiladelphia$1.3M
- Francis MarchlinskiPhiladelphia$1.2M
- David FrankelPhiladelphia$722K
- Fermin GarciaPhiladelphia$713K
- Timothy MarkmanPhiladelphia$693K
- Ralph VerdinoPhiladelphia$682K
- Robert SchallerPhiladelphia$579K
- Rajat DeoPhiladelphia$519K
- Matthew HymanPhiladelphia$474K
- Joshua CooperPhiladelphia$405K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.